Neurofibromin

spinqualitylabelsall models Neurofibromin (7pgs) Homo dimeric structure colored to differentiate dimers Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Introduction Neurofibromin (NF) is a cytoplasmic protein encoded by the NF1 gene located on chromosome 17 . It is localized to the cell membrane by the SPRED 1 protein. The neurofibromin protein in encoded by over 350 kb of DNA and contains 62 exons, 58 of which are constitutive. NF suppresses the Ras oncogene by increasing the rate of hydrolysis from Ras-GTP (active) to Ras-GDP (inactive). Increasing the rate of Ras inactivation decreases cell proliferation linked to cancer. Structure Neurofibromin is a large protein of 2818 amino acids and is a homodimer that exists in two conformations. Domains Neurofibromin consists of multiple domains: N-HEAT/ARM, GRD, Sec14-PH, GAPEx, and C-HEAT/ARM. The two most characterized domains of neurofibromin are the Sec14-PH and GRD domains. Each of the protomers of neurofibromin contains these domains. Figure 1. Domains of Neurofibromin. N-HEAT/ARM and C-HEAT/ARM Heat domains are domains found in cytoplasmic proteins that consist of four different proteins: Huntingtin, elongation factor 3, protein phosphatase 2A, and TOR1. . The HEAT/ARM cores are made up of many alpha helices. The N-HEAT/ARM and C-HEAT/ARM are rigid, which makes them critical in the rearrangement of the Gap-related and Sec14-PH domains. In the closed conformation, the HEAT/ARM domains cover the GRD, preventing the binding of Ras through steric hinderance. GRD domain The Gap-related domain, or GRD, is the catalytic domain of neurofibromin. It ranges from residues 1196 to 1547. This domain also contains a tubulin-binding domain. Its main catalytic mechanism is the hydrolysis of GTP-bound Ras into GDP-bound Ras, which converts Ras from its active form into its inactive form. The GRD provides an arginine residue, known as the arginine finger, to Ras. The location of the Gap-related domain is shifted between the open and closed conformations of neurofibromin. SEC-PH The Sec-PH domain is the lipid-binding domain of neurofibromin, found in residues 1565 to 1835. In the closed conformation of neurofibromin, the hydrophobic core is blocked by the Gap-related domain. The open conformation allows the hydrophobic core in the Sec cavity to be accessible and exposed. CSRD and CTD The Cysteine-Serine-rich domain (CSRD) and C-terminal domain (CTD) contain phosphorylation sites. The CSRD is able to be phosphorylated by protein kinases A and C Phosphorylation by protein kinase C is a positive regulator of neurofibromin activity. The CTD is phosphorylated primarily by protein kinase C. This domain is a negative regulator of neurofibromin activity if particular residues are phosphorylated. CTD contains a nuclear localization signal as well. Important Structural Features Conformations Closed Conformation The closed state of neurofibromin has both protomers in a closed conformation, which inhibits the binding of Ras to the GRD of neurofibromin due to the HEAT/ARM blocking the GRD. A metal binding site between the N-HEAT/ARM domain and the GRD-Sec14-PH linker stabilize the closed conformation. This site is coordinated by three residues, C1032, H1558, and H1576, and a water molecule. This binding site is preferential for zinc; zinc has been found to stabilize the closed conformation of neurofibromin. In the absence of zinc, Open Conformation The open state of neurofibromin has one protomer in a open conformation and the other in a closed conformation. The protomer in the open conformation allows for the binding of Ras because of reorientation of the GRD and Sec14-PH domains. In the open conformation, the metal binding site found in the closed conformation is lost due to separation of the N-HEAT/ARM and the cysteine residue from the histidine residues founds in the GRD-Sec14-PH linker. Transition Between Open and Closed Conformation In the transition from the closed state to the open state, several of the domains of neurofibromin rotate to make the binding site of neurofibromin more accessible . This rotation is able to occur due to the rotation of three connective linkers, L1, L2, and L3. L1 is located between an alpha helix 48 in N-HEAT and an alpha helix 49 in GRD. G1190 is a potential hinge point when L1 rotates and pushes the alpha helixes outwards to move the Gap-related domain. L3 is located between the Sec14-PH domain and the C-HEAT/ARM and aids in the movement of the Sec14-PH domain. Without this rotation, the membrane binding sites are occluded and inaccessible. The proximity of L1 and L3 has to be close to facilitate the rotation of the domains. SPRED-1 Protein The SPRED-1 protein localizes neurofibromin to the cell membrane in to allow it to bind to the membrane oriented Ras protein. SPRED-1 interacts with the N-terminal domain of NF to guide it to the membrane from the cytosol, where its C terminal domain will determine its target . Ras binding site Ras and Neurofibromin associate through an arginine residue, 1276 (previously referred to as 789), that comes from neurofibromin. This arginine is referred to as the “arginine finger” and assists in the hydrolysis of GTP by binding to a backbone carbon atom of tyrosine 32 of Ras when neurofibromin is in the open conformation. It points into the GTP binding site of Ras when neurofibromin is in the open conformation. R1276 also helps stabilize the position of Glutamine 61, a key catalytic residue, through hydrogen bonds, as well as GTP. Glutamine 61 of Ras is a residue that facilitates the conversion of GTP to GDP, turning Ras from its active state to inactive state. There is a catalytic water molecule that glutamine interacts with to position the molecule for a nucleophilic attack on the gamma phosphate of GTP. Mutations of this residue have been related to lower rates of hydrolysis. . Tyrosine 32 makes water-mediated hydrogen bonds with the gamma phosphate of GTP. This position is also where Ras is phosphorylation to promote the activity of GTPase-activating proteins and GTP hydrolysis. Disease Relevance Mutations to the neurofibromin protein are implicated in the progression of Neurofibromatosis type 1. Neurofibromatosis type 1 is a condition where cancer develops by inactivating the Ras suppression effects of NF, allowing Ras to behave as an oncogene. Neurofibromatosis type 1 is an autosomal dominant disorder that affects 1 in 3,000 people. The NF gene has the highest mutation rate of any human gene, adding to the prevalence of cancers related to neurofibromin mutations. Furthermore, these mutations consist heavily of de novo mutations. NF1 primarily causes tumors in the central and peripheral nervous systems, but often has a multisystem expression including tumors in the dermatologic, cardiovascular, gastrointestinal, and orthopedic systems. The wide range of presentations is consistent with the multiplicity of mutations observed in the causative protein. This multiplicity derives from the immense size and homo dimeric nature of the neurofibromin protein that allows for otherwise innocuous mutations to wreak havoc on the conformations of the protein as well as its ability to bind to the Ras protein given that the positioning of NF relative to Ras is highly important. Downstream Effects Figure 2: Downstream proliferation of Ras signals have a variety of impacts, including gene regulation, cell proliferation, and cell growth; By cybertory - This file was derived from: Signal transduction v1.png, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=12081090 Misregulated Ras activity can lead to uncontrolled signaling in many different cell signaling pathways. Figure 2 provides an overview of the pathways that are connected to Ras. As shown, neurofibromin's ability to regulate Ras activity can alter cell proliferation signaling, activation/ inactivation of transcription factors, and cell apoptotic factors, making its proper functioning crucial . Additionally, due to its overall importance in multiple cell pathways, neither neurofibromin nor Ras profile as possible drug targets.

Proteopedia Page Contributors and Editors (what is this?)

Jordyn K. Lenard, Ryan D. Adkins, OCA, Michal Harel, Jaime Prilusky